Cargando…

Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates

Detalles Bibliográficos
Autores principales:	Sava, Mihaela, Bättig, Veronika, Gerull, Sabine, Passweg, Jakob R., Khanna, Nina, Garzoni, Christian, Gerber, Bernhard, Mueller, Nicolas J., Schanz, Urs, Berger, Christoph, Chalandon, Yves, van Delden, Christian, Neofytos, Dionysios, Stampf, Susanne, Franzeck, Fabian C., Weisser, Maja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812769/ https://www.ncbi.nlm.nih.gov/pubmed/36310245 http://dx.doi.org/10.1038/s41409-022-01851-y

Ejemplares similares

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
por: Olearo, Flaminia, et al.
Publicado: (2020)

When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
por: Roth, Romain Samuel, et al.
Publicado: (2022)

Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
por: Glampedakis, Emmanouil, et al.
Publicado: (2021)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study
por: van Delden, Christian, et al.
Publicado: (2020)

Patient preferences for allogeneic haematopoietic stem cell transplantation: how much benefit is worthwhile from the patient’s perspective?
por: Leuthold, Nicolas, et al.
Publicado: (2020)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
por: Kronig, Ilona, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018
por: Kohler, Philipp, et al.
Publicado: (2021)

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma
por: Zanella, Marie-Céline, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
por: Simeunovic, Helena, et al.
Publicado: (2022)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Epidemiology and outcomes of bone and joint infections in solid organ transplant recipients
por: Pham, Truong‐Thanh, et al.
Publicado: (2022)

Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study
por: Walti, Laura N., et al.
Publicado: (2020)

Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update
por: Neofytos, Dionysios, et al.
Publicado: (2023)

Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation
por: Pradier, Amandine, et al.
Publicado: (2023)

Vaccine-Preventable Infections Among Solid Organ Transplant Recipients in Switzerland
por: Walti, Laura N., et al.
Publicado: (2023)

Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
por: Spahr, Yasmin, et al.
Publicado: (2018)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Expanding the use of allogeneic haematopoietic cell transplantation in dermatology
por: Bauer, J.W.
Publicado: (2021)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation
por: Ritari, J., et al.
Publicado: (2018)

Epidemiology and outcomes of medically attended and microbiologically confirmed bacterial foodborne infections in solid organ transplant recipients
por: van den Bogaart, Lorena, et al.
Publicado: (2021)

Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT
por: Mohty, B, et al.
Publicado: (2011)

Rehabilitation after Allogeneic Haematopoietic Stem Cell Transplantation: A Special Challenge
por: Bertz, Hartmut
Publicado: (2021)

Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation
por: Moriyama, Shohei, et al.
Publicado: (2022)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Medinger, Michael, et al.
Publicado: (2023)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease
por: Cuthbertson, Peter, et al.
Publicado: (2021)

Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation
por: de Jong, G., et al.
Publicado: (2020)

Metabolic Profiling Early Post-Allogeneic Haematopoietic Cell Transplantation in the Context of CMV Infection
por: Rasmussen, Kirstine K., et al.
Publicado: (2023)

P1312: CHARACTERISTICS OF MEMBRANOUS NEPHROPATHY AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Jin, Yue, et al.
Publicado: (2023)

The Phosphoproteome of Bloodstream Form Trypanosoma brucei, Causative Agent of African Sleeping Sickness
por: Nett, Isabelle R. E., et al.
Publicado: (2009)

Bloodstream Infections in Patients with Hematologic Diseases: Causative Organisms and Factors Associated with Resistance
por: Choi, Hyeah, et al.
Publicado: (2022)

Dissociations of oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation
por: Mauramo, Matti, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q7u8i79pnlfp8n6tev2fc7srq4